Kelburn Mental Health & Addiction Treatment Centre Announces New Ownership, New Leadership and New Modalities

Kelburn Mental Health & Addiction Treatment Centre Announces New Ownership, New Leadership and New Modalities

Kelburn Recovery Centre is pleased to announce that Dr. Ian Rabb addiction treatment and clinic operations veteran has recently joined as Managing Director.

Dr Ian Rabb recently named Chief Clinics Officer for Universal Ibogaine Inc ((TSXV: IBO), a life sciences company with a mission to research and deliver medicalized ibogaine-centered addiction care, effective November 15 th 2021.  Universal Ibogaine acquired the Kelburn Clinic in October of 2021.

Kate Bloy , renowned addiction treatment psychotherapist and psychedelic therapy pioneer, has also joined the team at Kelburn as Clinical Director.

Did you know: That 1 in 5 Canadians are affected by addiction?

Dr Ian Rabb stated, "At Kelburn Recovery Centre, we recognize addiction is a treatable illness; we provide substance use and mental health treatment in a private setting to ensure confidentiality. We are committed to a holistic approach to healing. Mental, physical, emotional and spiritual health are considered in every program. Each guest receives trauma informed therapies & evidence-based treatments individualized for their own situation."

Kelburn covers a wide range of needs, from outpatient therapy to short-term detox stays and multi-month treatment for mental health and substance use disorders.

Dr Ian Rabb – Managing Director, Kelburn Recovery Centre/ Chief Clinic Officer, Universal Ibogaine Inc.

Dr Ian Rabb is one of the most recognized and respected leaders in Addiction Treatment in Canada today.  Dr. Ian Rabb is a certified Interventionist and addictions specialist who has helped thousands of people overcome addiction. In his 20 years of sobriety, he founded Two Ten Recovery and Destiny House Winnipeg's only sober living housing organization, was the founding member of Aurora Recovery Centre and most recently held the position of Director of Business Development at Edgewood Health Network, Canada's only national addiction treatment center brand.

Dr. Rabb has served on the board of directors of the Addictions Foundation of Manitoba,  he was Chair of a forum for VOICES, which provides services for transitioning foster youth. Ian led the Homelessness Task Force in 2014, served on the inaugural board of End Homelessness Winnipeg, and sat on the Community Advisory Board for The Homelessness Partnering Strategy. He has further played an active role on the board of the Jewish Child and Family Services, the Children's Hospital Foundation, and the Health Science Centre Foundation.

Did you know: Opioid overdose is the leading cause of death in people under 50?

Ian says "In my 20 years in the addiction recovery business I have not seen anything that has the power of Ibogaine to disrupt the devastating effects of addiction. The opportunity to join the leadership team of Universal Ibogaine and as managing director of Kelburn Recovery Centre, where we intend to revolutionize addiction treatment, was something I could not refuse."

Ian added, "We would like to thank Josephine D'Andrea for her years of dedication and work at Kelburn Recovery Centre. She has decided to move forward with her next endeavor."

Kate Bloy – Clinical Director, Kelburn Recovery

Kate Bloy has been a professional psychotherapist for 14 years and is the Founder and CEO of Therapeutic Alliance, a private therapy practice in Winnipeg, Manitoba . She has been working in the addictions field for over 12 years, heading up therapy programs in Manitoba including the St. Raphael Wellness Centre and the Aurora Treatment Centre as well as successfully treating people with addiction issues within her private practice.

Kate is a leader in the psychedelic psychotherapy field, serving as the President of the Psychedelic Society of Winnipeg and as Coordinator of Psychedelic Harm Reduction Services with Winnipeg Folk Festival. She studied the clinical use of psychedelics, including ibogaine, with organizations including Medicinal Mindfulness, Fluence, Mt. Tam Integration, Iboga Soul and the Multidisciplinary Association for Psychedelic Studies.

In her own words, Kate describes herself as "a guide, helping people connect with their inner healing wisdom and integrating these experiences to optimize their potential and well-being."

Clinic Inquiries, please contact: Dr. Ian Rabb
ian.rabb@kelburnrecoverycentre.com

About Kelburn Recovery Centre:
Conveniently located in St. Adolphe , 7 kms south of Winnipeg . Kelburn Recovery Centre is a unique executive property on 45 beautiful acres along the Red River, approx. 30 minutes from Winnipeg James Armstrong Richardson International Airport. Kelburn Recovery Centre is ideally located for visits by family and outings into the Winnipeg area.

  • A 10,000 square foot executive residential home with bedrooms for 10 guests
  • Indoor sauna, Games room, Great room and more
  • A 9 -hole PGA standard, Executive Golf Course designed by Golf Course Architect, David Grant
  • Strategically placed BBQ's, allowing for family visits
  • Three beautiful lakes and a brook with all seasons walking paths
  • The property is lined with mature oak and pine trees for confidentiality, privacy and beauty

SOURCE Universal Ibogaine Inc.

Cision View original content: https://www.newswire.ca/en/releases/archive/January2022/19/c8920.html

News Provided by Canada Newswire via QuoteMedia

IBO:CA
The Conversation (0)
Universal Ibogaine Co-Founder Dr Alberto Sola to Present at upcoming Research to Reality Conference

Universal Ibogaine Co-Founder Dr Alberto Sola to Present at upcoming Research to Reality Conference

Universal Ibogaine Inc. (TSXV: IBO) (OTCQB: IBOGF) (FSE: JC4) (" UI " or the " Company ") a life sciences company with a mission to transform addiction treatment through the use of medicalized ibogaine and a global licensing model is pleased to announce that UI Co-Founder Dr Alberto Sola will... Keep Reading...
UNIVERSAL IBOGAINE RETAINS SHAYNE NYQUVEST AS CAPITAL MARKETS ADVISOR

UNIVERSAL IBOGAINE RETAINS SHAYNE NYQUVEST AS CAPITAL MARKETS ADVISOR

Universal Ibogaine Inc. (TSXV: IBO) (OTCQB: IBOGF) (FSE: JC4) (" UI " or the " Company ") a life sciences company with a mission to develop and deliver medicalized ibogaine-centered addiction care, advises that it has retained Mr. Shayne Nyquvest in a consulting role as Capital Markets Advisor.... Keep Reading...
Universal Ibogaine Advises of Departure of Marilyn Loewen Mauritz from the Board of Directors

Universal Ibogaine Advises of Departure of Marilyn Loewen Mauritz from the Board of Directors

(TheNewswire) Calgary, AB TheNewswire - April 21, 2022 Universal Ibogaine Inc. ( TSXV:IBO ) (" UI " or the " Company ") a life sciences company with a mission to develop and deliver medicalized ibogaine-centered addiction care, advises that Marilyn Loewen Mauritz has resigned as a member of the... Keep Reading...
UNIVERSAL IBOGAINE PROVIDES UPDATE ON KELBURN RECOVERY CENTER OPERATIONS

UNIVERSAL IBOGAINE PROVIDES UPDATE ON KELBURN RECOVERY CENTER OPERATIONS

Universal Ibogaine Inc. (TSXV: IBO) (" UI " or the " Company ") a life sciences company with a mission to develop and deliver medicalized ibogaine-centered addiction care, advises that it has temporarily closed the Kelburn Recovery Centre (" Kelburn ") due to an on-site flooding issue. Kelburn... Keep Reading...
Universal Ibogaine Announces Frankfurt Stock Exchange Listing

Universal Ibogaine Announces Frankfurt Stock Exchange Listing

Universal Ibogaine Inc. (TSXV: IBO) (OTCQB: IBOGF) (FSE: JC4) (" UI " or the " Company ") a life sciences company with a mission to transform the world of addiction treatment through medicalized ibogaine and a state of the art ongoing care program, is pleased to announce that its common shares... Keep Reading...
Quantum Biopharma

Quantum BioPharma Announces Cash Reward of up to USD $7Million for Proof of Market Manipulation in its Stock

Reward to be Paid if Information Contributes Significant Evidence Leading to a Trial Victory or Settlement in Landmark USD $700 Million+ Lawsuit

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol... Keep Reading...
Imagion Biosystems

Phase 2 HER2 Clinical Trial Manufacturing Commenced, WSU Imaging Optimisation Program Underway

Imagion Biosystems (ASX: IBX) (Company or Imagion), a company dedicated to improving healthcare outcomes through the early detection of cancer utilising its proprietary MagSense® imaging technology, is pleased to provide shareholders with a progress update regarding the Company’s business and... Keep Reading...
Stethoscope on stacked gold coins, symbolizing healthcare costs or medical finance.

Trump Tariffs to Raise US Medical Device Costs, Hospitals Hold Off on Stockpiling

President Donald Trump’s new round of tariffs —this time targeting copper— has intensified concerns about rising costs across key sectors, including healthcare. But despite significant price pressures on steel, aluminum, and now copper, all vital to medical device production, there is no... Keep Reading...
Actinogen

Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer’s disease trial and interim analysis timeline

Actinogen Medical ASX: ACW (“ACW” or “the Company”) is pleased to announce that the 100th participant in its pivotal XanaMIA phase 2b/3 randomized trial of Xanamem® for Alzheimer’s disease (AD) has now passed all screening tests and is scheduled for randomization and treatment in July. This... Keep Reading...
Emyria Limited

Medibank to Fund Emyria’s PTSD Program at Perth Clinic

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) a leader in developing and delivering innovative mental health treatments, is pleased to announce that Medibank Private Limited (“Medibank”), Australia’s largest private health insurer, has commenced funding for eligible customers to access... Keep Reading...
ASX:HIQ

HITIQ Announces Exclusive Global Agreement with Shock Doctor for PROTEQT Instrumented Mouthguard

Common Shareholder Questions – Entitlement Offer

HITIQ Limited (ASX: HIQ) (HITIQ or the Company), a pioneer in concussion management, proudly announces an exclusive global agreement with Shock Doctor, the world’s leading mouthguard innovator. This landmark agreement marks Shock Doctor’s two-year effort to design a mouthguard that will... Keep Reading...

Latest Press Releases

Related News